雷帕鸣中国上市时间

Sirolimus was approved in 2002 and officially launched in China, bringing new treatment opportunities and options to many domestic kidney transplant patients. Previously, the drug had been approved by the FDA in 1999 and was officially launched in the United States. The current reference price of the drug in China is between 143.00$ and 2739.00$. Patients can reimburse part of the cost through medical insurance, and only pay about 20% out of pocket. Due to the influence of regional medical insurance policies and other factors, there will be certain differences in the final reimbursement ratio of this drug. Specific patients can consult the relevant departments.

As a mammalian target of rapamycin (mTORi) inhibitor, rapamycin is a macrolide antibiotic isolated from actinomycete cultures. It was originally developed as an antifungal drug, but it showed immunosuppressive effects in animal models and was later approved as a maintenance immunosuppressant. Sirolimus has attracted clinical attention and is widely used because of its advantages such as non-nephrotoxicity, anti-tumor, and ability to reduce the incidence of cytomegalovirus infection.

Based on rapamin’s reliable efficacy and drug safety, patients can purchase and use this drug with confidence in China. However, it should be noted that this drug should be banned for patients who are allergic to sirolimus, sirolimus derivatives, or any ingredients in the oral solution of this drug, as well as pregnant and lactating women.

To minimize differences in the absorption of this drug, this drug should be taken consistently with or without food. Grapefruit juice slows the metabolism of sirolimus as regulated by CYP3A4 and should not be used to deliver or dilute sirolimus oral solutions. In addition, since rapamin is not absorbed through the skin, there are no special precautions. However, if it accidentally comes into direct contact with skin or mucous membranes, wash it thoroughly with soap and water; rinse your eyes with clean water.